argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,599

Sector

Biotechnology & Medical Research

Calendar

07-31 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
10/07/25	485.40 €	+4.39%	76,016
09/07/25	465.00 €	+0.19%	106,140
08/07/25	464.10 €	-0.39%	80,099
07/07/25	465.90 €	-0.26%	56,141
04/07/25	467.10 €	+1.46%	48,581

Real-time Euronext Bruxelles, July 10, 2025 at 04:55 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

485.40EUR

Average target price

664.70EUR

Spread / Average Target

+36.94%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 10/07/2025 BST			Pre-market 06:23:31
485.40 ^EUR	+4.39%		482.40	-0.62%

07-08	Deutsche Bank Upgrades Argenx to Buy, Raises PT	MT
07-08	European shares flat as investors assess new US tariff proposals	RE

Capitalization	29.71B 34.72B 27.68B 25.6B 47.52B 2,977B 52.9B 331B 126B 1,391B 130B 128B 5,084B	P/E ratio 2025 *	49.7x	P/E ratio 2026 *	28x
Enterprise value	26.77B 31.29B 24.95B 23.07B 42.83B 2,683B 47.68B 298B 114B 1,254B 117B 115B 4,583B	EV / Sales 2025 *	8.45x	EV / Sales 2026 *	6.25x
Free-Float	99.23%	Yield 2025 *	-	Yield 2026 *	-

Deutsche Bank Upgrades Argenx to Buy, Raises PT	07-08	MT
European shares flat as investors assess new US tariff proposals	07-08	RE
Unnatural Products, Inc. Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics	07-01	CI
Argenx to Move ARGX-119 Development to Registrational Study of Congenital Myasthenic Syndromes	06-30	MT
Argenx SE Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	CI
Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	06-23	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	06-20	MT
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	CI
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	06-20	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	06-11	MT
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	06-11	CI
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	06-10	RE

Deutsche Bank Upgrades Argenx to Buy, Raises PT	07-08	MT
Baird Upgrades argenx to Outperform From Neutral, Price Target is $680	05-13	MT
Bernstein Upgrades argenx to Outperform, Boosts PT	03-17	MT
Wedbush Raises Argenx's Price Target to $665 From $655, Maintains Outperform Rating	12-27	MT
Oppenheimer Adjusts argenx SE ADR Price Target to $675 From $646, Maintains Outperform Rating	11-21	MT

argenx SE Share Price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Valuation: argenx SE

Chart: argenx SE

Latest news: argenx SE

Last Transcript: argenx SE

Analysts' recommendations: argenx SE

Press Releases: argenx SE

News in other languages: argenx SE

Quotes and Performance

Course Extremes

Managers and Directors: argenx SE

ETFs: argenx SE

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Argenx : argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	PU
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	GL
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	AQ
Argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	GL
Argenx : argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-19	PU

Succesvolle IPO EnergyVision op lichtgroene beurs	07-09
Faute de carotte, le bâton fait son retour	07-08
Avis d'analystes du jour : nouveaux suivis sur Accor et Galderma, ArgenX relevé et Arkema dégradé	07-08
Deutsche Bank zet Argenx op de kooplijst	07-08
Umicore smaakmaker in Brussel	07-06

1 day	+4.39%
1 week	+3.76%
Current month	+3.32%
1 month	-5.45%
3 months	+2.17%
6 months	-24.44%
Current year	-19.10%

1 week	456.6	486.4
1 month	456.6	509.8
Current year	456.6	658
1 year	419.8	658
3 years	271	658
5 years	180.1	658
10 years	8.46	658

Manager	Title	Age	Since
Tim van Hauwermeiren CEO	Chief Executive Officer	53	14/07/2008
Karl Gubitz DFI	Director of Finance/CFO	55	31/05/2021
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	31/12/2014

Director	Title	Age	Since
Tim van Hauwermeiren BRD	Director/Board Member	53	30/06/2014
Peter K. M. Verhaeghe CHM	Chairman	67	14/10/2008
Joseph deBethizy BRD	Director/Board Member	75	12/05/2015

Name	Weight	AuM	1st Jan change
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD	0.93%	80 M€	+2.88%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.46%	21 M€	+4.29%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARGENX SE	+4.39%	+3.76%	+16.68%	+39.32%	34.72B
WUXI APPTEC CO., LTD.	+0.63%	-0.09%	+88.24%	-36.35%	28B
BIONTECH SE	+1.91%	+3.56%	+40.12%	-33.04%	28.05B
SUMMIT THERAPEUTICS INC.	+4.61%	+5.42%	+212.18%	+2,437.25%	19.22B
INSMED INCORPORATED	+0.20%	-1.17%	+32.23%	+289.76%	18.36B
WUXI BIOLOGICS (CAYMAN) INC.	+5.45%	+4.84%	+153.75%	-64.89%	13.32B
GENMAB A/S	+1.68%	+7.60%	-20.92%	-44.09%	13.43B
AKESO, INC.	+1.20%	+3.30%	+193.44%	+370.39%	12.38B
EXELIXIS, INC.	+2.50%	-2.12%	+104.85%	+105.22%	12.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.25%	-2.69%	+156.22%	-	9.78B
Average	+1.88%	+3.56%	+97.68%	+340.40%	18.96B
Weighted average by Cap.	+1.97%	+3.45%	+83.48%	+311.51%

	2025 *	2026 *
Net sales	3.17B 3.7B 2.95B 2.73B 5.07B 317B 5.64B 35.29B 13.48B 148B 13.88B 13.6B 542B	4.1B 4.8B 3.82B 3.54B 6.57B 411B 7.31B 45.73B 17.47B 192B 17.99B 17.62B 703B
Net income	714M 835M 666M 615M 1.14B 71.58B 1.27B 7.96B 3.04B 33.45B 3.13B 3.07B 122B	1.16B 1.36B 1.08B 1B 1.86B 116B 2.07B 12.93B 4.94B 54.35B 5.09B 4.98B 199B
Net Debt	-2.93B -3.43B -2.73B -2.53B -4.69B -294B -5.22B -32.67B -12.48B -137B -12.85B -12.59B -502B	-4.05B -4.73B -3.77B -3.49B -6.47B -406B -7.21B -45.1B -17.22B -190B -17.74B -17.38B -693B